An accelerated approval looks off the table, as the group’s first-line melanoma trial continues.

The NMPA has refused to back PFS, plus subgroup OS analyses, in fruquintinib’s stomach cancer study.

Duelling pivotal trials of anti-TROP2 ADCs should yield their first data imminently.

A US adcom will next month try to unravel confusion about PD-L1 status in first-line gastric cancer.

It’s back to school for biotech, with a packed conference schedule.

Other new first-in-human trials involve CD74, where Gilead and Sutro tried and failed, and the emerging target MAT2A.

Bicara and DualityBio will soon test market appetite for new oncology issues.

Belrestotug’s lung cancer trial features among the ESMO late-breakers, as do Immutep, Scorpion and others.

Second time lucky for Zynyz, Amgen’s PRMT5 comeback, and other possible surprises.

The leading proponents of selective SMARCA2 inhibition are taking their oral projects into clinical trials.